Ritonavir in HIV infection

Arvieux, C., and Tribut, O. Amprenavir or fosamprenavir plus ritonavir in HIV infection Pharmacology, efficacy and tolerability profile. Drugs 65(5) 633-659, 2005. [Pg.102]

Burger and his colleagues have illustrated an example of bridging different populations with PK/PD modeling to assess the dose adjustment need. They compared the PK/PD relationships of indinavir, a human immunodeficiency virus protease inhibitor, with or without ritonavir, in HIV-infected Thai patients to those in Caucasian patients, and recommended no dose adjustment despite the general lower body weight in the Thai population. ... [Pg.2810]

M. Cooper, D. Lange, J. Phanupak, P. Reiss, P. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. 91. J. Antimicrob. Chemother. 2003, 57, 1231-1238. [Pg.2815]

Bochet MV, Jacquiaud C, Valantin MA, Katlama C, Deray G. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med 1998 105(5) 457. [Pg.2162]

Merry C, Barry MG, Mulcahy F, RyanM, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM, Back DJ. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. (1997) 11, F29-F33. [Pg.825]

Moltd J, Valle M, Miranda C, Cedeno S, Negredo E, Barbanoj MJ, Qotet B. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 2011 55(1) 326-30. [Pg.475]

Mir O, Dessard-Diana B, Louet AL, Loulergue P, Viard IP, Langlois A, Durdux C, Le Beller C. Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. Br J Clin Pharmacol 2010 69(1) 99-101. [Pg.475]

Brunet C, Reliquet V, Jovelin T, Venisse N, Winer N, Bui E, et al. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women INEMA cohort. Med Mai Infect 2012 42(9) 421-8. [Pg.442]

Rifampin Daily for 4 months For persons who are contacts of patients with isoniazid-resistant rifampin susceptible TB. In HIV-infected patients, protease inhibitors or NNRTIs generally should not be administered concurrently with rifampin rifabutin can be used as an alternative for patients treated with indinavir, nelfinavir, amprenivir, ritonavir, orefavirenz, and possibly with nevirapine or soft-gel saquinavir5 B (II) B (III)... [Pg.1110]

Children The safety and pharmacokinetic profiles of lopinavir/ritonavir in children under 6 months of age have not been established. In HIV-infected patients 6 months to 12 years of age, the adverse event profile seen during a clinical trial was similar to that for adult patients. The evaluation of the antiviral activity of lopinavir/ritonavir in... [Pg.1834]

Moreno S, Podzamczer D, Blazquez R, Iribarren JA, Ferrer E, Reparaz J, Pena JM, Cabrero E, Usan L. Treatment of tuberculosis in HIV-infected patients safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS 2001 15(9) 1185-7. [Pg.2162]

In contrast, a detailed report on a large series of patients has provided impressive evidence that the use of protease inhibitors in HIV-infected patients with hereditary bleeding disorders can lead to an increased bleeding tendency (41). This effect, which is most likely to occur when ritonavir is used, is also unexplained. [Pg.2968]

Lopinavir is a protease inhibitor combination. Lopinavir inhibits HIV protease, the enzyme required to form functional proteins in HIV-infected patients. Ritonavir inhibits the cytochrome P450 (CYP) 3A-mediated metabolism of lopinavir, increasing lopinavir plasma concentrations. They are indicated in the treatment of HIV infections in combination with other antiviral agents. [Pg.396]

Muirhead G, Abel S, Russell D, Hackman F, Taylor-Worth R, TohM, TanLH. An investi -tion of the effects of atazanavir and ritonavir boosted atazanavir onthephanncokineticsofthe novel CCR5 inhibitor UK-427,857. 7 International Congress on Drug Ther y in HIV infection, Glasgow, UK, 14-18 November 2004. [Pg.781]

Hsu A, Bertz R, Renz C, Lam W, Rode R, Deetz C, Schweitzer SM, Berstein B, Brun S, Granneman GR, Sun E. Assessment of the pharmacokinetic interaction between lopinavir/ritonavir (ABT 378/r) and nevirapine (NVP) in HIV-infected pediatric subjects. AIDS (2000) 14 (Suppl. 4), SIOO. [Pg.788]

The concurrent use of saquinavir soft capsules (Fortovase) [no longer available] 1.2 g three times daily and erythromycin 250 mg four times daily doubled the AUC and maximum serum levels of saquinavir in HIV-infected subjects. The manufacturer notes that there are no data on the interaction using ritonavir-boosted saquinavir hard capsules or tablets In-virase). ... [Pg.820]

Arrington-Sanders R, Hutton N and Siberry GK (2006) Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr... [Pg.130]

Sekar V, Lefebvre E, Marien K, De Pauw M, Vangeneugden T, Pozniak A, Hoetelmans RMW. Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2009 68(1) 116-9. [Pg.474]

Molto J, Deig E, Valle M, Maria Llibre J, Miranda C, Cedeno S, Valero S, Negredo E, Clotet B. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir. Ther Drug Monit 2010 32(1) 93-6. [Pg.614]

Yombi JC, Maiter D, Belkhir L, Nzeusseu A, Vandercam B. Iatrogenic Cushing s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol 2008 27 (Suppl 2) S79-82. [Pg.616]

Valin N, De Castro N, Gamut V, Bergeron A, Bouche C, Molina IM. Iatrogenic Cushing s syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (Chic) 2009 8(2) 113-21. [Pg.616]

Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008 49(4) 358-68. [Pg.616]

Calza L, Trapani F, Salvadori C, MagistreUi E, Manfredi R, ColangeK V, et al. Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scand J Infect Dis... [Pg.438]

Sibiude J, Warszawski J, Tubiana R, DoUfus C, Faye A, Rouzioux C, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy role of the ritonavir boost Clin Infect ESs 2012 54(9) 1348-60. [Pg.442]

Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine E, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J (2003a) A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in nonnucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 8 279-287... [Pg.197]

HIV infection Saquinavir mesylate in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV infection. The twice-daily administration of saquinavir mesylate in combination with ritonavir is supported by safety data from the MaxCmin 1 study and pharmacokinetic data. The efficacy of saquinavir mesylate with ritonavir or saquinavir soft gelatin capsules (with or without ritonavir coadministration) has not been compared against the efficacy of antiretroviral regimens currently considered standard of care. [Pg.1800]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...